| Methods |
Double‐blind, cross‐over, placebo‐controlled trial |
| Participants |
22 participants randomly assigned; 19 analysed (3 dropped out before study end); mean age 51.5 years (range 18 to 83 years); 4 men and 15 women; mean tremor duration 24.2 years; baseline functional score 8.00 (standard deviation (SD) 2.36) |
| Interventions |
Participants with essential tremor received, in random order, alprazolam (starting dose 0.125 mg/d), acetazolamide (starting dose 62.5 mg/d), primidone (starting dose 62.5 mg/d) and placebo for 4 weeks, with a 2‐week washout period between treatments |
| Outcomes |
Functional score (including writing a sentence, drawing spirals, feeding, engaging in social activity); participant‐rated global improvement score (0 to 3) |
| Notes |
Only final scores were reported (very high risk of carry‐over effect), and data from the first treatment phase after randomisation were not available. We contacted the corresponding author of this paper in an attempt to obtain further information and are still awaiting a reply |
